Clinical Trial Update: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) [Phase 2]

View source ↗

Summary

Phase 2 trial of Selinexor in combination with gemcitabine for selected advanced soft-tissue sarcoma is currently recruiting in the SeliSarc study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Selinexor (Xpovio) (Selinexor)

Snippet

Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas | Conditions: Sarcoma,Soft Tissue | Phase 2 | Status: RECRUITING